Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial

Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial

Abstract Background Treatment options for pretreated triple-negative breast cancer (TNBC) are limited. This study aimed to evaluate the efficacy and safety of apatinib, an antiangiogenic agent, in combination of etoposide for pretreated patients with advanced TNBC. Methods In this single-arm phase I...

Full description

Bibliographic Details
Main Authors: Mengru Cao, Hailing Lu, Shi Yan, Hui Pang, Lichun Sun, Chunhong Li, Xuesong Chen, Wei Liu, Jing Hu, Jian Huang, Ying Xing, Ningzhi Zhang, Yingqi Chen, Ting He, Danni Zhao, Yuanyuan Sun, Lin Zhao, Xiaomeng Liu, Li Cai
Format: Article
Language:English
Published: BMC 2023-05-01
Series:BMC Cancer
Subjects:
Apatinib
Etoposide
Triple negative breast neoplasms
Angiogenesis inhibitors
Clinical trial
Online Access:https://doi.org/10.1186/s12885-023-10768-8

Internet

https://doi.org/10.1186/s12885-023-10768-8

Similar Items